Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan

Abstract Background Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression‐free survival (PFS); however, treatment with carfilzomib results in a higher incidence of cardiovascula...

詳細記述

書誌詳細

主要な著者:	Hiromi Hagiwara, Takafumi Nakayama, Hiroya Hashimoto, Shigeru Kusumoto, Hidekatsu Fukuta, Takeshi Kamiya, Koichi Ikuta, Shinsuke Iida
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2023-10-01
シリーズ:	Cancer Medicine
主題:	carfilzomib large claims database lenalidomide multiple myeloma overall survival renal impairment
オンライン･アクセス:	https://doi.org/10.1002/cam4.6457
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!